ArticleFrontiers in endocrinology2025
Patient outcomes after attending pre-pump education class: disparities in initiation and glycemic outcomes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Automated Insulin Delivery Use Among Preschool-Age Children With Type 1 Diabetes: A T1D Exchange Multicenter Analysis.Journal of diabetes science and technology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: At Children's of Alabama, all patients with insulin dependent diabetes are considered for continuous subcutaneous insulin infusion therapy (CSII, also known as insulin pump). In some cases, eligibility depends on insurance requirements, including six months of MDI therapy, CSII education, and a six-week glucose log with four daily readings. Objective: Evaluate factors influencing CSII initiation after "Prepump class" and assess glycemic changes in CSII starters. Methods: A retrospective review of pre-pump class attendees from January 2022 to July 2023 was completed. Patients who initiated a CSII prior to January 2024 were identified as "CSII-starters," and those who remained in multiple daily injections were identified as "MDI-retainers". Demographic and medical data were compared between these groups. For CSII-starters, type of system and use of automatic insulin delivery (AID) was evaluated. Glycemic outcomes were assessed in those with type 1 diabetes (T1D) with continuous glucose monitor data. A sub-analysis was done for those outside the honeymoon period. Outcomes of AID systems and users of non-AID systems were compared. Results: Of 283 pediatric patients who attended pre-pump class, 187 (66%) started CSII, with a median initiation time of 108 days (interquartile range 76-154). CSII-starters and MDI-retainers differed by race (p=0.0385) and insurance (p=0.0001), but not by sex, language, or age at diagnosis. Initiators were younger (p=0.0150), had shorter diabetes duration (p=0.0001), lower HbA1c (p=0.0020), and higher CGM use (p<0.0001). Among starters, 70% chose tubeless pumps, and 62% (n=116) used AID systems. Race and insurance were not linked to AID vs non-AID choice, but were associated with CSII initiation. Insurance and race were not associated with selecting an AID over non-AID CSII systems. In glycemic analysis, 183 patients were studied. AID systems showed improved outcomes compared to non-AID systems for the full analysis and sub-analysis of patients outside the honeymoon period. Conclusion: While race and insurance are not associated with the selection of an AID vs non-AID system, they are associated with CSII-starters versus MDI-retainers. As expected, AID systems outperformed non-AID systems in our cohort. Future work will aim to reduce disparities in CSII and AID access for all interested in diabetes technology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.